conclusions this investigation might contribute to delineate the best treatment options for this high risk population. evidence acquisition we reviewed current evidences on the use of antiplatelet therapy in patients with esrd/hd undergoing pci, focusing on the efficacy and safety of specific agents and their indications for detailed clinical settings. results clinical setting in hd patients is...

Drug Free Tumor Theranostics In article number 2205165, Tymish Y. Ohulchanskyy and co-authors introduce hemoglobin nanocrystals for drug free, synergistic selective theranostics of colon cancer. After intravenous (i.v.) injection, these target tumor react with tumor-specific H2S H2O to enable magnetic resonance imaging guided photothermal therapy produce •OH chemodynamic therapy.

Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tol...

Intra-tumour heterogeneity is a leading cause of treatment failure and disease progression in cancer. While genetic mutations have long been accepted as primary mechanism generating this heterogeneity, the role phenotypic plasticity becoming increasingly apparent driver intra-tumour heterogeneity. Consequently, understanding resistance key component improving cancer therapy. We develop mathemat...